Rep. Lisa C. McClain Sells Thermo Fisher Scientific Inc. (NYSE:TMO) Shares

Representative Lisa C. McClain (R-Michigan) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Thermo Fisher Scientific Trading Down 0.3%

TMO stock opened at $585.85 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm’s 50-day moving average is $539.29 and its 200 day moving average is $475.16. The company has a market capitalization of $220.11 billion, a PE ratio of 33.84, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company posted $5.28 earnings per share. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has approved a share buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the sale, the executive vice president owned 21,152 shares in the company, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 41,845 shares of company stock worth $23,947,352 over the last 90 days. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently made changes to their positions in TMO. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares in the last quarter. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $28,000. Highline Wealth Partners LLC grew its position in Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at approximately $30,000. Finally, Capital A Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after buying an additional 66 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on TMO. Leerink Partners raised their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Barclays upped their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. TD Cowen upped their target price on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $601.65.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.